Showing 3831-3840 of 6411 results for "".
- Arcutis Initiates Patient Enrollment in Phase 2b Study in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-initiates-patient-enrollment-in-phase-2b-study-in-chronic-hand-eczema/2460466/Arcutis Biotherapeutics, Inc. initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema. Topline data from this trial are expected in the
- Azitra Awarded Patent for Engineered Bacterial Strain Discovery Platformhttps://practicaldermatology.com/news/azitra-awarded-patent-for-engineered-bacterial-strain-discovery-platform/2460463/Azitra, Inc. has been issued a patent for the company’s engineered bacterial strain discovery platform. The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,702,558, which includes broad composition of matter claims that are central to the the company’s pr
- Mount Sinai Researcher Receives NIH Grant to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19https://practicaldermatology.com/news/mount-sinai-researcher-receives-nih-grant-to-study-immune-responses-of-patients-with-inflammatory-skin-diseases-in-the-setting-of-covid-19/2460458/Patients with moderate to severe atopic dermatitis who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be hospitalized due to complications. Now, researchers from the Icahn School of Medicine
- Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for Atopic Dermatitishttps://practicaldermatology.com/news/secondary-efficacy-and-patient-reported-outcomes-in-phase-2b-clinical-trial-of-tapinarof-cream-for-atopic-dermatitis/2460435/Secondary efficacy and patient-reported outcomes from Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis were recently reported in The Journal of the American Academy of Dermatology (JAAD). Tapinarof cream is a potential first-in-class, on
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the Americ
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- To Test or Not to Test? Practices Weigh COVID-19 Testing of Patients and Staff as Part of Reopening Planshttps://practicaldermatology.com/news/to-test-or-not-to-test-practices-weigh-covid-19-testing-of-patients-and-staff-as-part-of-reopening-plans/2460395/COVID-19 antibody testing can play an important role in identifying people who have recovered from the SARS-CoV-2 virus and who have high levels of antibodies in their blood that could potentially help other critically ill COVID-19 patients. The presence of antibodies may also suggest immuni
- Galderma: Patients Treated with Dysport Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Yearhttps://practicaldermatology.com/news/galderma-patients-treated-with-dysport-achieved-high-levels-of-satisfaction-and-natural-looking-results-with-two-treatments-per-year/2460391/Topline results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for injection, showed that 95 percent of patients treated with Dysport achieved high levels of satisfaction with two treat
- Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for Psoriasishttps://practicaldermatology.com/news/dermavant-completes-patient-enrollment-for-two-phase-3-clinical-trials-of-tapinarof-for-psoriasis/2460339/Dermavant Sciences completed patient enrollment in PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis. Dermavant expects t
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c